Novavax, Inc. (NVAX) Earnings Call Transcripts
Novavax, Inc.'s Latest Earnings Call - June 4, 2026
In the Q2 2026 earnings call for Novavax, Inc. (NVAX), management highlighted significant advancements in their growth strategy initiated in January 2025, emphasizing unprecedented interest from third-party companies and new partnerships, notably with Pfizer. The company reported a $30 million upfront payment from Pfizer and potential milestones totaling $250 million, indicating a strong revenue-generating potential. Guidance for non-GAAP profitability was reiterated for 2028, with a projected non-GAAP expense target reduced to $150 million to $200 million, reflecting a 50% reduction compared to 2025.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $30M (beat) |
| Potential Milestones | $250M (positive) |
| Non-GAAP Expense Target | $150M - $200M (positive) |
| C. diff Market Potential | $1.5B - $3B (positive) |
| Combined Market Opportunity | $12B (positive) |
| Projected Non-GAAP Profitability | 2028 (positive) |
Guidance from management
Management maintained guidance for non-GAAP profitability by 2028, supported by a diversified revenue stream from partnerships and reduced operating costs.
What management said
Yes. Maybe I'll just add that we're also on the antigen side. We're also using our internal R&D engine to explore additional antigens that can be utilized with Matrix. And some of those will be antigens that will use as test cases to help us learn and advance and move the science forward. And others, for example, in the case of our C. diff vaccine will be ones that we may choose to advance internally and take into th...
And one comment just to add, Elaine had mentioned, 6 to 12 months for some anticipated data, but we already have data generated by some smaller innovative partners in oncology that we had partnered with quite a while ago through MTAs as part of our new strategy launch. And so we have some insights already as to some of the antigen targets and things in oncology. And then we just announced, to your point Elaine, this ...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape and the execution risk associated with multiple partnerships. There were questions about the timeline for clinical advancements and the potential impact of external competition on Novavax's market share.
Main topics on the call
- Partnerships and Revenue Generation — Management noted a 'new partnership with Pfizer' which includes a $30 million upfront payment and 'potential milestones to the tune of $250 million'. This partnership is expected to significantly enhance revenue streams ...
- Matrix-M Technology Expansion — The company is seeing 'unprecedented interest' in its Matrix-M technology, with four new material transfer agreements (MTAs) signed, including one with a top 10 global pharmaceutical company. This indicates a growing rec...
- Cost Structure Improvements — Novavax has improved its non-GAAP expense target to 'between $150 million and $200 million' by 2028, a significant reduction from previous years. This is part of a broader strategy to streamline operations and focus on h...
- C. diff Vaccine Development — The company is advancing its C. diff vaccine candidate, which targets over 90% of circulating strains and aims to enter the clinic by 2027. Management emphasized the 'significant unmet need' in this area, positioning it ...
Read the full Novavax, Inc. transcript (June 4, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Novavax, Inc.
Novavax, Inc. (NVAX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 69 calls on record spanning January 16, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 69 Novavax, Inc. earnings call transcripts on record, spanning January 16, 2020 to August 6, 2026. Based on this history, Novavax, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- NVAX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 69
- First call
- January 16, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly